AP Exclusive: Clinton book has sold more than 300,000 copies
NEW YORK (AP) — Hillary Clinton's "What Happened" had a big debut. Clinton's book about her stunning loss in 2016 to Donald Trump sold more than 300,000 copies in th
new Patent or at least an update 1 9,765,109 Full-Text 2'-arabino-fluorooligonucleotide N3'.fwdarw.P5' phosphoramidates: their synthesis and use Sept 19 2017
Kim Jung UN had NO military experience whatsoever before Daddy made him a four-star general. This snot-nosed twerp had never accomplished anything in his life that would even come close to military leadership. He hadn't even so much as led a Cub Scout troop, coached a sports team, or commanded a military platoon. So he is made the "Beloved Leader" Of North Korea.
Terrific! Oh nuts! I'm sorry... I just remembered that we did the same thing.
We took an arrogant phony community organizer, who had never worn a uniform, never ran so much as an ice-cream stand, and made him Commander-in-Chief. A guy, who had never had a real job, worked on a budget, or led anything more than an ACORN demonstration, and we made him "Beloved Leader" of the United States - Twice! So if you think North Koreans are stupid... I'm sorry I brought this up....never mind!
New SA article. Quote: "Geron is a true binary event for next year.". For all techies the bit is either on or off. For all other the decision is either yes or no. Nice article.
Geron is a true binary event for next year. Ipsen’s Xarmelo approved in EU for carcinoid syndrome diarrhea. GlaxoSmithKline's Trelegy Ellipta approved for COPD.
just picked up some more
Actually it is the dearth of reliable information that is killing us. I could go on and on about multiple indications, increasing trial participants, combo therapies, or extending trial duration's, but it would all be conjecture. JNJ is dribbling out little bits and pieces of data to the detriment of the gern shareholder. I don't foresee any changes to that paradigm.
INCY $117.00 slow ride down
JNJ is adding 20 new patients to one of the trials.
Geron to Present at the Cantor Fitzgerald Healthcare Conference
Watching the Space
Much of our board's focus has been on Median OS for the MF patient group. That's a headline number, for sure, but, what will be even more important, imho, is what kind of disease modification took place in the patients, esp. those surviving the longest. Maybe the spleen shrink is slower to materialize, but what do those bone marrows look like?? There will be many other tests, checkpoints, benchmarks, etc. that will give JNJ and the FDA the full picture of what Imetelstat did for this patient group that is otherwise flat out of options.
Living longer, yes, but the details of the MF trial will hopefully result in a some significant corroboration to the Mayo analysis and energize more important combination studies which Janssen no doubt would love to develop and lead.
Arctic sea ice extent is up 40% from this date five years ago. 2012 2017 Greenland's surface gained ten times as much ice as it did five years ago, and was the fifth highest on record. Guest post: How…
We are being played!
INCY $114.67 -2.42 (-2.07%)
jnj writing the check 4 gern in 1 month
So many paid bashers here. The MMs say dance and you do the hokey pokey.
The assumed "safety time frame" of this stock, (before a JnJ/Jensen announcement or decision(s)) could be a mirage. Market has been lulled into indifference waiting for ONE event. White noise fills the time vacuum. Potential "shock index" increases daily.
I think this is the lowest volume day I've ever seen (and I've been in GERN since before the discovery of stemcells at U of Wisc,).
Looks like a rousing investor response to Johnny's press release today. Never thought "unchanged" would be extraordinary good in the land of Geron. Woofs, if your're still making Juve tea take it public and give Geron investors something to get behind.